Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …

Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series; a two-dose series is now recommended in some age groups and there is interest in …

Objectives This study aimed to systematically review the literature on the efficacy and
immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose …

Objectives Despite their use, differences in human papillomavirus (HPV) vaccine efficacies
remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent …

Simpler schedules for human papillomavirus (HPV) vaccine delivery could improve vaccine
coverage and the effectiveness of cervical cancer prevention. The objective of this study was …

Introduction Vaccine effectiveness and impact studies are typically observational, generating
evidence after vaccine launch in a real-world setting. For human papillomavirus (HPV) …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Recently, many studies have evaluated HPV vaccine safety and adverse effects. Two
vaccine shave been recently evaluated in randomized controlled trials: the bivalent vaccine …

Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71
countries. Unfortunately, uptake has been impacted in some countries by reduced …